𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Regional CBF changes in Parkinson’s disease: the importance of functional neuroimaging analyses

✍ Scribed by Bárbara J. Amorim; Erica C. S. Camargo; Elba C. S. C. Etchebehere

Publisher
Springer
Year
2007
Tongue
English
Weight
75 KB
Volume
34
Category
Article
ISSN
0340-6997

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Determination of minimal clinically impo
Determination of minimal clinically important change in early and advanced Parkinson's disease
✍ Robert A. Hauser; Peggy Auinger; on behalf of the Parkinson Study Group 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 96 KB

## Abstract Two common primary efficacy outcome measures in Parkinson's disease (PD) are change in Unified Parkinson's Disease Rating Scale (UPDRS) scores in early PD and change in “off” time in patients with motor fluctuations. Defining the minimal clinically important change (MCIC) in these outco

Homeostatic changes of the endocannabino
Homeostatic changes of the endocannabinoid system in Parkinson's disease
✍ Valerio Pisani; Graziella Madeo; Annalisa Tassone; Giuseppe Sciamanna; Mauro Mac 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 143 KB

Endocannabinoids (eCBs) are endogenous lipids that bind principally type-1 and type-2 cannabinoid (CB 1 and CB 2 ) receptors. N-Arachidonoylethanolamine (AEA, anandamide) and 2-arachidonoylglycerol (2-AG) are the best characterized eCBs that are released from membrane phospholipid precursors through